Study of serum C-reactive protein concentration in cardiac failure.

Pye, Maurice; Rae, Alan P.; Cobbe, S M

doi:10.1136/hrt.63.4.228

Cited by 67 publications

(44 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with prior publications showing that hsCRP elevation seems to be related to overt heart failure presentation rather than left ventricular systolic function per se. [27][28][29][30] Furthermore, a history of a recent acute MI was independently associated with elevated hsCRP, whereas coronary lesion characteristics (multivessel disease, presence of peripheral or cerebral vascular disease, and prior revascularization) were not. These data support the concept that preprocedural inflammation is associated to a large extent with the biological activity of coronary and cardiac disease processes rather than their anatomical severity.…”

Section: Patients Characteristics and Inflammationmentioning

confidence: 99%

High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice

Herrmann

Lennon

Barsness

et al. 2012

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-High sensitivity C-reactive protein (hsCRP) has been identified as a predictor of adverse cardiovascular outcomes. Whether hsCRP is a useful biomarker for risk stratification in contemporary percutaneous coronary intervention remains unknown. Methods and Results-We conducted a prospective study among 513 patients undergoing non-emergency percutaneous coronary intervention and examined the relationship between pre-and postprocedural hsCRP levels and outcomes. The patients were divided according to the median preprocedural hsCRP level (0.3 mg/dL

show abstract

Section: Patients Characteristics and Inflammationmentioning

confidence: 99%

High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice

Herrmann

Lennon

Barsness

et al. 2012

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…CRP seems to be increased in HF patients [18][19][20]. Anand et al [19] suggested that higher CRP concentration is associated with more severe HF, and independently with increased morbidity and mortality.…”

Section: Our Analysis Of 638 Decompensated Hf Patients Demonstratesmentioning

confidence: 99%

Basic laboratory parameters as predictors of in-hospital death in patients with acute decompensated heart failure: data from a large single-centre cohort

Ostrowska

Ostrowski

Łuczak³

et al. 2017

Kardiol Pol

View full text Add to dashboard Cite

A b s t r a c tBackground: Heart failure (HF) is a growing cause of hospitalisation worldwide, and despite significant progress in its treatment it is still associated with high mortality. Aim:The aim of this study was to find factors predicting in-hospital death in acute decompensated HF by analysis of basic laboratory data and echocardiography, routinely collected on admission to the hospital. Methods:To this single-centre retrospective study we involved 638 consecutive patients hospitalised in the years 2007-2008 due to acute decompensated HF. To the initial univariate analysis we included the results of echocardiography and 36 basic laboratory tests performed at hospital admission. Parameters significantly associated with in-hospital death in univariate analysis were taken to multivariate regression analysis. Results:In-hospital death occurred in 119 cases (median age 75 years; 40.3% females). The multivariate analysis revealed significant association between in-hospital death and: higher leukocyte count (death [D]: 13.5 vs. survival [S]: 8

show abstract

“…2 BNP-related peptides and CRP are elevated in congestive heart failure (CHF), and the levels correlate with symptom severity and prognosis. [3][4][5][6][7][8] Additionally, elevated CRP level predicts risk of CHF, 9 -11 and recently, Wang et al 12 reported BNP level predicts risk of death and cardiovascular events, including CHF, in an asymptomatic population. However, limited data are available directly comparing CRP and BNP-related peptides in persons at risk of CHF.…”

mentioning

confidence: 99%

Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease

et al. 2005

View full text Add to dashboard Cite

Abstract-B-type natriuretic peptide (BNP) and C-reactive protein (CRP) are elevated in persons at risk for congestive heart failure (CHF). However, limited data are available directly comparing BNP-related peptides and CRP in persons at risk of CHF. To evaluate amino terminal-pro-BNP (NT-proBNP) and CRP, separately and together, for assessment of risk of CHF, we performed a nested case-control study of the 6105 participants of the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS), a placebo-controlled study of a perindopril-based blood pressure-lowering regimen among individuals with previous stroke or transient ischemic attack (TIA). Each of 258 subjects who developed CHF resulting in death, hospitalization, or withdrawal of randomized therapy during a mean follow-up of 3.9 years was matched to 1 to 3 control subjects. NT-proBNP and CRP predicted CHF; the odds ratio for subjects in the highest compared with the lowest quarter was 4.5 (95% confidence interval, 2.7 to 7.5) for NT-proBNP and 2.9 (confidence interval, 1.9 to 4.7) for CRP, and each remained a predictor of CHF after adjustment for all other predictors. Screening for both markers provided better prognostic information than screening for either alone. Elevation of NT-proBNP above 50 pmol/L and CRP above 0.84 mg/L predicted CHF with sensitivity of 64% and specificity of 66%. NT-proBNP and CRP predicted CHF in subjects receiving perindopril-based therapy. We conclude that NT-proBNP and CRP are independent predictors of CHF risk after stroke or TIA. Moreover, NT-proBNP and CRP may be markers of mechanisms of CHF pathogenesis distinct from those responsive to angiotensin-converting enzyme inhibitor-based therapy. Key Words: heart failure Ⅲ natriuretic peptides Ⅲ cerebrovascular disorders Ⅲ stroke Ⅲ renin B -type natriuretic peptide (BNP) is synthesized as a high molecular weight precursor, proBNP, which is cleaved to release BNP and the amino-terminal fragment NT-proBNP, and both peptides are released from the cardiac ventricles in response to increased wall stress. 1 C-reactive protein (CRP) is released from the liver in response to inflammation. 2 BNP-related peptides and CRP are elevated in congestive heart failure (CHF), and the levels correlate with symptom severity and prognosis. [3][4][5][6][7][8] Additionally, elevated CRP level predicts risk of CHF, 9 -11 and recently, Wang et al 12 reported BNP level predicts risk of death and cardiovascular events, including CHF, in an asymptomatic population. However, limited data are available directly comparing CRP and BNP-related peptides in persons at risk of CHF. 13 We evaluated the prognostic performance of NTproBNP and CRP in a population with cerebrovascular disease and increased risk of CHF by conducting a nested case-control study of 258 subjects who developed CHF and 516 control subjects who did not develop CHF, who were participants in the Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS). PROGRESS was designed to determine the effects of active therapy with a perindopr...

show abstract

Study of serum C-reactive protein concentration in cardiac failure.

Cited by 67 publications

References 13 publications

High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice

High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice

Basic laboratory parameters as predictors of in-hospital death in patients with acute decompensated heart failure: data from a large single-centre cohort

Prediction of Heart Failure by Amino Terminal-pro–B-Type Natriuretic Peptide and C-Reactive Protein in Subjects With Cerebrovascular Disease

Contact Info

Product

Resources

About